ATHA Stock Analysis: Buy, Sell, or Hold?
ATHA - Athira Pharma, Inc. Common Stock
$6.75
-0.44 (-6.12%)
▼
5d:
-3.02%
30d:
+73.75%
90d:
+72.19%
HOLD
MODERATE Confidence
Last Updated: January 9, 2026
Earnings: Feb 26, 2026
21d
Get Alerted When ATHA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ATHA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ATHA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ATHA is currently trading at $6.75, which is considered oversold relative to its 30-day fair value range of $6.78 to $7.41.
Technical Outlook: Technically, ATHA is in a strong uptrend. Immediate support is located at $6.41, while resistance sits at $7.77. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $4.00. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ATHA is in a strong uptrend. Immediate support is located at $6.41, while resistance sits at $7.77. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $4.00. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$6.78 -
$7.41
Company Quality Score
56/100
(HOLD)
Volume Confirmation
LOW
Confidence Score
56.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BEARISH: Low volume - lacks confirmation
- BEARISH: Downward momentum (-6.1%)
- BEARISH: Trading 40.7% above Wall St target ($4.00)
Fair Price Analysis
30-Day Fair Range
$6.78 -
$7.41
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$6.41
Resistance Level
$7.77
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-1.34
Wall Street Target
$4.00
(-40.7%)
Last updated: February 04, 2026 5:52 AM ET
Data refreshes hourly during market hours. Next update: 6:52 AM
Data refreshes hourly during market hours. Next update: 6:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATHA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 65 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 53 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
